arrow
S

Sergio Parra

GlaxoSmithKline
H指数:16
被引数:1,179

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Safety, Tolerability and Pharmacokinetics of a High-Dose, Rapid-Infusion Monoclonal Antibody: Phase I Results for Intravenous Sotrovimab 3000 mg

安全性、耐受性及药代动力学:高剂量、快速输注型单克隆抗体:静脉注射Sotrovimab 3000 mg的I期研究结果

2025-12-010
OA
A randomised, double-blind, placebo-controlled study to determine the analgesic efficacy, safety and tolerability of VPX638 administered topically to painful wounds

一项随机,双盲,安慰剂对照研究,以确定局部施用于疼痛伤口的VPX638的镇痛功效,安全性和耐受性

2025-02-120
OAAI
Intramuscular vs Intravenous SARS-CoV-2 Neutralizing Antibody Sotrovimab for Treatment of COVID-19 (COMET-TAIL): A Randomized Noninferiority Clinical Trial

肌内和静脉内SARS-CoV-2中和抗体Sotrovimab治疗新型冠状病毒肺炎 (彗星尾): 一项随机非劣效性临床试验

2023-07-145
OAAI
Safety, Virology, Pharmacokinetics, and Clinical Experience of High-Dose Intravenous Sotrovimab for the Treatment of Mild to Moderate COVID-19: An Open-Label Clinical Trial

高剂量静脉注射Sotrovimab治疗轻中度新型冠状病毒肺炎的安全性、病毒学、药代动力学和临床经验: 一项开放标签临床试验

2023-07-105
OAAI
Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19 A Randomized Clinical Trial
2022-04-05198
OA
β2-Adrenoceptor signaling in airway epithelial cells promotes eosinophilic inflammation, mucous metaplasia, and airway contractility

气道上皮细胞中的 β2-肾上腺素受体信号促进嗜酸性粒细胞性炎症,粘液化生和气道收缩

2017-10-0949
OAAI